CN1323688C - Medicine composition for treating prostatosis and method for preparing the same - Google Patents
Medicine composition for treating prostatosis and method for preparing the same Download PDFInfo
- Publication number
- CN1323688C CN1323688C CNB2005100774501A CN200510077450A CN1323688C CN 1323688 C CN1323688 C CN 1323688C CN B2005100774501 A CNB2005100774501 A CN B2005100774501A CN 200510077450 A CN200510077450 A CN 200510077450A CN 1323688 C CN1323688 C CN 1323688C
- Authority
- CN
- China
- Prior art keywords
- gram
- grams
- radix
- radix notoginseng
- cotton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicinal composition for treating prostate diseases and a preparation method thereof. The medicinal composition of the present invention comprises active constituents and /or additives accepted in pharmacy, and the active constituents and /or the additives are made of the following raw materials of 100 to 500 grams of longhairy antenoron herb, 300 to 500 grams of mianbi, 150 to 300 grams of pink herb, 200 to 300 grams of phellodendron bark, 30 to 55 grams of notoginseng, 150 to 300 grams of peach seed, 200 to 300 grams of szechwan chinaberry fruit, 150 to 250 grams of combined spicebush root and 200 to 300 grams of twotoothed achyranthes root, and 1000 granules are made totally. The product of the present invention has an important and positive significance to the relief of patients'pain and the protection of labor force, the present invention has the advantages of outstanding curative effects, safety, convenience, little side effect and low price, and the present invention is a compound medicine of purely traditional Chinese medicine.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, more particularly about a kind of pharmaceutical composition for the treatment of prostatosis and preparation method thereof.
Background technology
Prostatosis is male's genito-urinary system commonly encountered diseases, mainly comprises prostatitis, prostatic hyperplasia and carcinoma of prostate.Most of all one's life of male are all otherwise with the puzzlement that is subjected to prostatosis of degree, wherein especially with chronic prostatitis for seeing more.In the male in 20-65 year, discovery is arranged all, 22-40 year man sickness rate height, incidence trend is the rejuvenation development.
The traditional Chinese medical science is not listed prostatitis separately as a disease, and it is included into diseases such as pouring, turbid, lumbago due to renal deficiency.In general, think that acute prostatitis belongs to " pyretic stranguria " scope, chronic prostatitis belongs to " smart turbid ", " stranguria with turbid discharge " scope.Write in " Jing Yue's complete work miscellaneous diseases plan stranguria with turbid discharge ": " have turbid smart person, must be by hyperactivity of the ministerial fire, lust is contrary smart so that smartly can not close the Tibetan from its position, then source and course in succession, excessive excessive and descend.Move the hot bladder puckery pain in hole of then drowning, pure and impure and extremely, this all nebulousurine because of heat symptom-complex also.And for a long time also, spleen-QI sinking being arranged then, soil is not made wet, and the unclear person of water channel." think and its sick essence that belongs to from the beginning of being many with heat symptom-complex, upset smart chamber damp and hot accumulateing in Liver Channel at kidney, mostly be acute prostatitis or chronic prostatitis acute attack for sick; Do not control for a long time, then damp-heat accumulation injures the spleen kidney in the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, makes spleen-QI sinking and not removing dampness shows as chronic prostatitis.So theory of Chinese medical science thinks that prostatitic morbidity is many to be pented up in smart chamber, hinder in passages through which vital energy circulates because of damp invasion of lower energizer, the QI and blood that with the passing of time must stagnate, blood loses due to the essence stasis; Or stagnation of blood stasis, in case invade in damp and hot, blood battalion is not smooth, makes the damp-heat accumulation stasis of blood part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels.So many methods develop simultaneously with clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling.If its disease must not be controlled, prolonged illness is gone into kidney and is caused void, so that simulataneous insufficiency and excessive, pathogenesis is a deficiency in origin and excess in superficiality, and the rule of treatment is when eliminating evil tonify deficiency, to receive the effect of giving consideration to both the incidental and fundamental.Clinical syndrome differentiation execute also think in controlling chronic prostatitis with damp-heat accumulation disease for seeing more.
The medicine of existing treatment prostatosis belongs to a bit cures the symptoms, not the disease, and some uses expensive material, and some interrupts use because uncertain therapeutic efficacy is cut in application process.
Summary of the invention
The purpose of this invention is to provide pharmaceutical composition of little, the cheap pure treatment by Chinese herbs prostatosis of a kind of determined curative effect, safe ready, side effect and preparation method thereof.
These and other purpose of the present invention will further embody and set forth by following detailed description and explanation.
The pharmaceutical composition of treatment prostatosis of the present invention comprises the active component and/or the pharmaceutically acceptable additives that are made by following raw materials according:
Herba Lysimachiae 300-500 restrains cotton Bi 300-500 gram
Herba Dianthi 150-300 gram Cortex Phellodendri 200-300 gram
Radix Notoginseng 30-55 gram Semen Persicae 150-300 gram
Fructus Toosendan 200-300 gram Radix Linderae 150-250 gram
Radix Achyranthis Bidentatae 200-300 gram
Make 1000 altogether.
Further, the pharmaceutical composition of treatment prostatosis of the present invention comprises the active component and/or the pharmaceutically acceptable additives that are made by following raw materials according:
Herba Lysimachiae 400-450 restrains cotton Bi 350-450 gram
Herba Dianthi 180-250 gram Cortex Phellodendri 230-280 gram
Radix Notoginseng 35-45 gram Semen Persicae 180-250 gram
Fructus Toosendan 230-280 gram Radix Linderae 180-250 gram
Radix Achyranthis Bidentatae 230-280 gram
Make 1000 altogether.
Be preferably, the pharmaceutical composition of treatment prostatosis of the present invention comprises the active component and/or the pharmaceutically acceptable additives that are made by following raw materials according:
Herba Lysimachiae 400-420 restrains cotton Bi 400-420 gram
Herba Dianthi 200-230 gram Cortex Phellodendri 230-260 gram
Radix Notoginseng 40-45 gram Semen Persicae 200-220 gram
Fructus Toosendan 230-250 gram Radix Linderae 200-220 gram
Radix Achyranthis Bidentatae 230-260 gram
Make 1000 altogether.
The pharmaceutical composition of treatment prostatosis of the present invention adds conventional pharmacy adjuvant, can make granule, tablet, capsule, powder or pill as starch, dextrin or capsule, can also add correctives or spice if necessary certainly.
Described in the present invention " grain " can be the grain on the conventional meaning, also can be " bag ", or the granule on other conventional meanings.
The preparation of drug combination method of treatment prostatosis of the present invention comprises the following steps:
A, take by weighing in following ratio:
Herba Lysimachiae 300-500 restrains cotton Bi 300-500 gram
Herba Dianthi 150-300 gram Cortex Phellodendri 200-300 gram
Radix Notoginseng 30-55 gram Semen Persicae 150-300 gram
Fructus Toosendan 200-300 gram Radix Linderae 150-250 gram
Radix Achyranthis Bidentatae 200-300 gram
B, get Herba Lysimachiae, cotton Bi and Cortex Phellodendri and add 70% alcohol reflux 3-5 time, each 1-2 hour, alcohol adding amount be the medical material amount 4-7 doubly, filter, merge alcohol extract, placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 2-4 time, each 0.5-1.5 hour, amount of water be the medical material amount 6-10 doubly, filter, being concentrated into relative density is 1.15-1.20 (50 ℃ of surveys), cools, and adds ethanol and makes and contain the alcohol amount and reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate, drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, Radix Notoginseng powder that adding (D) step obtains and dextrin or starch are an amount of, stevioside's 15 grams, mixing is used alcohol granulation, drying is made 1000 of granules altogether.
Further, the preparation of drug combination method of treatment prostatosis of the present invention comprises the following steps:
A, take by weighing in following ratio:
Herba Lysimachiae 300-500 restrains cotton Bi 300-500 gram
Herba Dianthi 150-300 gram Cortex Phellodendri 200-300 gram
Radix Notoginseng 30-55 gram Semen Persicae 150-300 gram
Fructus Toosendan 200-300 gram Radix Linderae 150-250 gram
Radix Achyranthis Bidentatae 200-300 gram
B, get Herba Lysimachiae, cotton Bi and Cortex Phellodendri and add 70% alcohol reflux 4 times, each 1.5 hours, alcohol adding amount be the medical material amount 5-7 doubly, filter, merge alcohol extract, placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 3 times, each 1.0 hours, amount of water be the medical material amount 8-9 doubly, filter, being concentrated into relative density is 1.15-1.20 (50 ℃ of surveys), cools, and adds ethanol and makes and contain the alcohol amount and reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, add the Radix Notoginseng powder that (D) step obtains, mixing, drying in incapsulating, obtains 1000 capsules altogether.
In the preparation of drug combination method of treatment prostatosis of the present invention, raw material consumption wherein is:
Herba Lysimachiae 400-450 restrains cotton Bi 350-450 gram
Herba Dianthi 180-250 gram Cortex Phellodendri 230-280 gram
Radix Notoginseng 35-45 gram Semen Persicae 180-250 gram
Fructus Toosendan 230-280 gram Radix Linderae 180-250 gram
Radix Achyranthis Bidentatae 230-280 gram
Make 1000 altogether.
Further, in the preparation of drug combination method of treatment prostatosis of the present invention, raw material consumption wherein is:
Herba Lysimachiae 400-420 restrains cotton Bi 400-420 gram
Herba Dianthi 200-230 gram Cortex Phellodendri 230-260 gram
Radix Notoginseng 40-45 gram Semen Persicae 200-220 gram
Fructus Toosendan 230-250 gram Radix Linderae 200-220 gram
Radix Achyranthis Bidentatae 230-260 gram
Make 1000 altogether.
Product of the present invention is for removing the patient suffering, and the protection labour force has important and active operation significance.And determined curative effect, safe ready, side effect are little, cheap, are a kind of pure traditional Chinese compound medicines.
The all raw material of Shi Yonging comprises that additive etc. all is conventional uses, can buy from market in the present invention.
More than form to be by weight as proportioning, when producing, can or reduce according to the corresponding proportion increase, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, and for especial patient, the proportioning of the amount of can corresponding adjustment forming increases or reduce being no more than 100%, and drug effect is constant.
Raw material of Chinese medicine, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
In the present invention, refer in particular to as non-, all amount, percentage ratios are unit of weight.
Below further specify the present invention by specific embodiment, but embodiment only be used for the explanation, can not limit the scope of the invention.
The specific embodiment
Embodiment 1:
A, take by weighing in following ratio:
Herba Lysimachiae 320 grams, cotton Bi 320 grams, Herba Dianthi 160 grams,
Cortex Phellodendri 220 grams, Radix Notoginseng 35 grams, Semen Persicae 160 grams,
Fructus Toosendan 220 grams, the Radix Linderae 160 grams, Radix Achyranthis Bidentatae 200 grams;
B, getting Herba Lysimachiae, cotton Bi and Cortex Phellodendri, to add concentration be 70% alcohol reflux 4 times, and each 1.5 hours, alcohol adding amount was 5.5 times of medical material amount, filtered, and merged alcohol extract, and placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 3 times, each 1.0 hours, amount of water was 8 times of medical material amount, filter, being concentrated into relative density is 1.15-1.20 (50 ℃ of surveys), cools, and adds ethanol and makes solution contain amount of alcohol to reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate, drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, Radix Notoginseng powder that adding (D) step obtains and dextrin or starch are an amount of, stevioside's 15 grams, mixing is used alcohol granulation, drying is made 1000 of granules altogether.
Embodiment 2
A, take by weighing in following ratio:
Herba Lysimachiae 480 grams, cotton Bi 480 grams, Herba Dianthi 280 grams,
Cortex Phellodendri 280 grams, Radix Notoginseng 50 grams, Semen Persicae 280 grams,
Fructus Toosendan 280 grams, the Radix Linderae 220 grams, Radix Achyranthis Bidentatae 280 grams;
B, getting Herba Lysimachiae, cotton Bi and Cortex Phellodendri, to add concentration be 70% alcohol reflux 5 times, and each 1 hour, alcohol adding amount was 6.5 times of medical material amount, filtered, and merged alcohol extract, and placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 2-4 time, each 0.5-1.5 hour, amount of water was 6-10 a times of medical material amount, filters, being concentrated into relative density is 1.15-1.20 (50 ℃ of surveys), cool, add ethanol and make and contain ethanol content and reach 70%, cold preservation is spent the night, sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, add the Radix Notoginseng powder that (D) step obtains, mixing, drying in incapsulating, obtains 1000 capsules altogether.
Embodiment 3
A, take by weighing in following ratio:
Herba Lysimachiae 420 grams, cotton Bi 420 grams, Herba Dianthi 210 grams,
Cortex Phellodendri 250 grams, Radix Notoginseng 42 grams, Semen Persicae 210 grams,
Fructus Toosendan 250 grams, the Radix Linderae 210 grams, Radix Achyranthis Bidentatae 250 grams;
B, get Herba Lysimachiae, cotton Bi and Cortex Phellodendri and add 70% alcohol reflux 4 times, each 1.5 hours, alcohol adding amount was 6 times of medical material amount, filtered, and merged alcohol extract, and placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 3 times, each 1.5 hours, amount of water was 8 times of medical material amount, filter, being concentrated into relative density is 1.15-1.20 (50 ℃ of surveys), cools, and adds ethanol and makes and contain ethanol content and reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate, drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, add Radix Notoginseng powder and starch that (D) step obtains, stevioside's 15 grams, mixing is used alcohol granulation, drying obtains 1000 granules altogether.
Embodiment 4
A, take by weighing in following ratio:
Herba Lysimachiae 400 grams, cotton Bi 400 grams, Herba Dianthi 230 grams,
Cortex Phellodendri 220 grams, Radix Notoginseng 40 grams, Semen Persicae 240 grams,
Fructus Toosendan 260 grams, the Radix Linderae 230 grams, Radix Achyranthis Bidentatae 220 grams;
B, get Herba Lysimachiae, cotton Bi and Cortex Phellodendri and add 70% alcohol reflux 2 times, each 2.0 hours, alcohol adding amount was 7 times of medical material amount, filtered, and merged alcohol extract, and placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 2 times, each 2.0 hours, amount of water was 8 times of medical material amount, filter, being concentrated into relative density is 1.15-1.20 (50 ℃ of surveys), cools, and adds ethanol and makes and contain ethanol content and reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate, drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, add Radix Notoginseng powder and starch that (D) step obtains, stevioside's 15 grams, mixing is used alcohol granulation, drying obtains 1000 granules altogether.
Embodiment 5
Be subjected to the reagent thing: the turbid treating stranguria granule that disappears, provide by China Academy of TCM's Chinese medicine-institute, lot number 20040910,8 gram granule/bags contain 2.25 gram crude drug/gram granules.
Dosage design: the clinical consumption of people be one time one bag, amount to 24 gram granules, 54 gram crude drug/skies every day three times, by 60 kilograms of calculating, dosage is 0.9 to restrain crude drug/kilogram.
The turbid treating stranguria granule mice dosage that disappears is 20.0,10.0,5.0 gram crude drug/kilograms; Rat dosage is 10.0,5.0,2.5 gram crude drug/kilograms; Rabbit dosage is 6.0,3.0,1.5 gram crude drug/three dosage groups of kilogram.Press the conversion of animals and human beings kg body weight, middle dosage is equivalent to clinical equivalent dosage approximately, and high dose is a times of middle dosage, and low dose is 1/2 of a middle dosage.
Positive control drug: QIANLIETONG PIAN, many pharmaceutical factory product, the lot numbers: 980108-3L of winning in Guangzhou.
Clinical consumption is 18,0.5 gram/sheet, 18 is 9 grams, by 60 kilograms of calculating, dosage is 0.15 gram/kilogram, presses the animals and human beings kg body weight and calculates, the mice consumption is 1.6 gram/kilograms, the rat consumption is 0.8 gram/kilogram, and rabbit 0.6 gram/kilogram is equivalent to clinical equivalent dosage, during use with distilled water diluting to desired concn.
Ciprofloxacin injection, Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s packing, German Bayer AG makes, and lot number 960711 is formulated into desired concn with water for injection during experiment.
The administration volume: the mice consumption is 0.2 milliliter/10 gram body weight, and the rat consumption is 1.0 milliliters/100 gram body weight, and the rabbit consumption is 4.0 milliliters/1000 gram body weight
Reagent: XIAOZHILING ZHUSHEYE, Beijing the 4th pharmaceutical factory's product, lot number: 97101401; Oleum Tiglii, carrageenin all are Japan and light Co., Ltd. product, and lot number is respectively DCCL7737,45F-0427; High molecular dextran, Sigma company, D-5251, molecular weight are 580000.
Bacteria culture: staphylococcus aureus, beta hemolytic streptococcus, escherichia coli, degeneration bacillus are strain separated clinically, available from Institute of Medicinal Biological Technique, Beijing.
Culture medium: meat soup, Britain produces.
Animal: mice, Switzerland's kind, male, body weight 20 ± 1 grams; Rat, Wistar system, 140 ± 10 gram body weight or 200-400 gram, male, provide by Institute of Experimental Animals, Chinese Academy of Medical Sciences, the animal quality certification number is respectively＜cure and moves word〉01-3008,01-3001.White big ear rabbit is provided by 301 Hospital of Military Medical Science Institute, and the animal quality certification number is the moving word of medical officer B98014 number.
Instrument: UV-754 continous way spectrophotometer, Shanghai the 3rd analytical tool factory makes.WX-753B microscope picture recording system, optical instrument factory, Xuzhou, JEOLJEM2000EX (electron microscopic observation).
Test method and result
One, to the influence of rat prostate inflammation
(1) to the prostatitic influence of rat aseptic
Method: 200-250 is restrained rat by the body weight random packet, gastric infusion, every day 2 times, continuous 7 days, matched group gives the distilled water of same volume, after the 1st administration in the 6th day 1 hour, the sterile working undergos surgery under the etherization, seminal vesicle on the prostate head lobe injects that 0.1 milliliter of 1% carrageenin normal saline solution/only, postoperative is sewed up, and the normal control group is at 0.1 milliliter of same area injection physiological saline solution/only, in postoperative 24 hours whole rat anesthesias are cut open the belly, respectively get prostatic fluid 10 microlitres, the total white blood cells with microscopy unit volume prostatic fluid the results are shown in Table 1; Each gets 1 smear of prostatic fluid in addition again, and mirror is observed the little body density of Lecithin down, according to Lecithin corpusculum density judged result, with rank test comparison administration group and matched group there was no significant difference is arranged.The results are shown in Table 2.
Lecithin corpusculum density grade scale:
" ++ ++ ": the little body density of Lecithin is kitchen range bunch shape;
" +++": the little body density of Lecithin is intensive;
" ++ ": the little body density of Lecithin is dispersed in;
"+": the little body density of Lecithin as seen;
" ± ": the little body density of Lecithin is accidental.
The table 1 pair prostatitic influence of rat aseptic
| Group | Dosage (gram/kilogram) | Mus number (only) | Total white blood cells (individual/10 μ l) | Suppression ratio (%) | The P value |
| The model contrast | -- | 10 | 3620±640 | ||
| Normal control | -- | 6 | 400±141 | 89.0 | ＜0.01 |
| Turbid treating stranguria granule disappears | 10.0 5.0 2.5 | 10 10 10 | 1830±434 2250±450 2370±559 | 19.4 37.8 34.5 | ＜0.01 ＜0.01 ＜0.01 |
| QIANLIETONG PIAN | 0.8 | 10 | 2600±512 | 28.2 | ＜0.01 |
Table 1 result as seen, total white blood cells obviously increases in the model control group prostatic fluid, three the dosage groups of turbid treating stranguria granule that disappear total white blood cells obviously reduces, the positive control drug QIANLIETONG PIAN also has identical effect.
Table 2. disappears turbid treating stranguria granule to the prostatitic influence of rat experiment
| Group | Dosage (gram/kilogram) | Mus number (only) | The little body density of Lecithin (level) | The P value | ||||
| ± | + | ++ | +++ | ++++ | ||||
| The model contrast | -- | 10 | 1 | 5 | 4 | |||
| Normal control | -- | 5 | 1 | 5 | ＜0.01 | |||
| Turbid treating stranguria granule disappears | 10.0 5.0 2.5 | 10 10 10 | 2 | 4 5 4 | 4 4 4 | 2 1 | ＜0.01 ＜0.01 ＜0.05 | |
| QIANLIETONG PIAN | 0.8 | 10 | 2 | 3 | 4 | 1 | ＜0.05 | |
Table 2 as seen, contain a large amount of Lecithin (+++, ++ ++) in the normal prostatic liquid, the a large amount of lipids of macrophage phagocytic during prostatitis, the Lecithin corpusculum is reduced or disappear (± ,+), the little body density of Lecithin is compared obvious reduction with the normal control group in the model control group prostatic fluid, three the dosage groups of turbid treating stranguria granule that disappear are compared obvious rising to the little body density of Lecithin with model control group, the positive control drug QIANLIETONG PIAN also has identical.
(2) disappear turbid treating stranguria granule to the prostatitic influence of rat chronic
Method: after 350-400 restrained the rat modeling, by body weight random packet, gastric infusion, every day 2 times, continuous 30 days, matched group gave the distilled water of same volume, put to death rat after 30 days and got the prostata tissue specimen and observe.
Modelling: with pentobarbital sodium 100 mg/kg lumbar injections, after anaesthetizing successfully, at the aseptic condition median incision of lower abdomen, through abdominal cavity, propose bladder and both sides seminal vesicle, expose the prostate notopodium that invests the seminal vesicle inboard, inject 0.2 milliliter of 25% XIAOZHILING ZHUSHEYE respectively, the normal saline of matched group injection equal volume, suture muscles, skin.
Observational technique
1. anatomic observation: prostate shape, color and luster and around the adhesion situation.
2. microscopic examination: 10% formalin solution fixed preparation, the ethanol series dehydration, dimethylbenzene is transparent, paraffin embedding.Slice thickness 4-5 micron, HE dyeing, ordinary optical microscope is observed the prostata tissue morphological change.
3. electron microscopic observation: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences's electronic microscopy room is observed.
Inflammatory cell infiltration grading standard:
Severe: inflammatory cell is kitchen range bunch shape;
Moderate: inflammatory cell is intensive;
Slightly: inflammatory cell is dispersed in;
Substantially normal: inflammatory cell as seen;
Normally: inflammatory cell is accidental.
According to above inflammatory cell infiltration degree judged result, there was no significant difference is arranged with rank test comparison administration group and matched group.The results are shown in Table 3.
The result
1. dissection finding: normal prostate tissue softness, ruddy, glossy.The glandular tissue of model control group 70% and surrounding tissue have adhesion in various degree, and tissue surface lacks gloss, and there is canescence point-like tuberosity on indivedual glandular tissue surfaces.Administration group glandular tissue and surrounding tissue adhesion degree are light, and how normal tissue surface gloss is, do not see the canescence tuberosity.
2. microscopic examination:
Normal control group prostatic epithelium is cube or column, and there is irregular fine hair on the surface, and the lumen of gland form differs, and the wrinkle wall is many, in many secretions are arranged, body of gland has smooth muscle cell outward, belongs to the normal structure structure.
The model control group glandular epithelium is nipple sample hypertrophy, and exudate is arranged in the pipe, and a matter has a large amount of neutrophilic infiltrations, the obvious hypertrophy of fibrous tissue; The minority lumen of gland diminishes, and glandular cell destroys, and the lumen of gland endocrine reduces or do not have.
The heavy dose of group of turbid treating stranguria granule that disappears glandular epithelium does not see that hypertrophy is arranged, and a matter inflammation is clearly better, and the capillary endothelial cell and the fibroblast that substitute inflammatory cell increase to some extent, and muscular tissue increases to some extent.
The dosage group glandular epithelium form that disappears in the turbid treating stranguria granule is basic with heavy dose of group.
The turbid treating stranguria granule small dose group glandular epithelium that disappears has a small amount of nipple sample hypertrophy, and periphery has moderate fibroblast and capillary endothelial cell, and a matter inflammatory cell obviously reduces.
Positive drug QIANLIETONG PIAN adenomatosis is clearly better, and has a large amount of capillary endothelial cells and fibroblast hypertrophy, inflammation to take a favorable turn in the matter.
Table 3 disappears turbid treating stranguria granule to the prostatitic influence of rat chronic
| Group | Dosage (gram/kilogram) | Mus number (only) | Cell infiltration | The P value | ||||
| Severe | Moderate | Slightly | Substantially normal | Normally | ||||
| The model contrast | -- | 10 | 6 | 2 | 1 | 1 | ||
| Normal control | -- | 5 | 1 | 4 | ＜0.01 | |||
| Turbid treating stranguria granule disappears | 10.0 5.0 2.5 | 10 10 10 | 1 2 3 | 5 4 5 | 3 3 1 | 1 1 1 | ＜0.01 ＜0.01 ＜0.05 | |
| QIANLIETONG PIAN | 0.8 | 10 | 1 | 2 | 4 | 3 | ＜0.05 | |
Table 3 result as seen, model control group chronic prostatitis degree obviously increases the weight of, inflammatory cell infiltration obviously alleviates after the administration.Point out the turbid treating stranguria granule that disappears that chronic prostatitis is had the obvious treatment effect.
3. electron microscopic observation:
Normal control group: epithelial cell clear in structure, the cell intersection is visible closely to be connected, cytoplasm is even, has abundant endoplasmic reticulum to be multilamellar and arranges, and minority has slight expansion, the Golgi complex structure is normal, the mitochondrion mild swelling, epithelial cell forms lumen of gland, and the chamber face has more rich microvillus, the flesh layer is thicker, and blood capillary is abundant.
Model control group: the most of disintegrate of epithelial cell, no intact cell is only seen granule and broken membrane structure, in the broken cell of minority the extremely endoplasmic reticulum of expansion is arranged, degeneration mitochondrion and lysosome, nucleus swelling partly is the dissolubility pathological changes.
Turbid treating stranguria groups of grains disappears: epithelial cell forms lumen of gland, and the chamber face has the microvillus of irregular arrangement, and cytoplasm substrate is more even, more rich endoplasmic reticulum is arranged, and minority has slight expansion, and structure of mitochondria is normal substantially, part mild swelling, flesh layer are grown better, and blood capillary is abundant.With the increase of dosage, lesion degree alleviates.
Positive drug QIANLIETONG PIAN group: epithelial cell slurry even compact, there is abundant endoplasmic reticulum to be multilamellar and arranges, part is slight expansion.
Two, the turbid treating stranguria particulate antiinflammatory action that disappears
1. the influence that the capillary of skin permeability is increased
Method: mice is by after the body weight random packet, once irritate turbid treating stranguria granule of disappearing of stomach various dose and positive control drug QIANLIETONG PIAN, matched group gives the distilled water of medicinal liquid equal volume, after 1 hour, tail vein injection 0.5% is according to blue liquid 0.2 milliliter/10 grams of the train of thought, melted paraxylene 40 microlitres on the unhairing skin of abdomen immediately, put to death animal after 15 minutes, getting orchid dyes skin and shreds, be put in distilled water: in acetone (3: the 7) solution, centrifuging and taking supernatant after 20 hours, photometry density value under wavelength 590 nanometers carries out statistical procedures.
Table 4 influence that turbid treating stranguria granule increases the mouse skin capillary permeability that disappears
| Group | Dosage (gram/kilogram) | Mus number (only) | Optical density value (OD) (X ± SD) | Suppression ratio (%) | The P value |
| Matched group | -- | 10 | 0.307±0.085 | ||
| Turbid treating stranguria granule disappears | 20.0 | 10 | 0.140±0.034* | 54.39 | ＜0.01 |
| 10.0 | 10 | 0.141±0.033* | 54.07 | ＜0.01 | |
| 5.0 | 10 | 0.144±0.034 | 53.09 | ＜0.01 | |
| QIANLIETONG PIAN | 1.6 | 10 | 0.183±0.052 | 40.39 | ＜0.01 |
Annotate: compare * P＜0.05 in QIANLIETONG PIAN
Table 4 result as seen, turbid treating stranguria granule and the QIANLIETONG PIAN of disappearing all can significantly suppress increasing of mouse skin capillary permeability that dimethylbenzene causes, the turbid treating stranguria particulate antiinflammatory action that disappears obviously is better than the positive control drug QIANLIETONG PIAN.
2. to the influence of rat carrageenan foot swelling
Method: the rat random packet, with rat ankle joint girth (millimeter) before and after the self-control tape measurement system inflammation.Gastric infusion was injected 0.01 milliliter of the scorching agent of 1% carrageenin system in the right ankle joint of every rat in 1 hour behind the medicine, and the scorching back of system was measured the rat ankle joint girth respectively in 1,2,3,4 hour, calculated swelling value (the scorching back of system girth with system scorching before girth poor).
The turbid treating stranguria granule that disappears is once irritated the stomach rat, and the on Carrageenan foot swelling has significant inhibitory effect (seeing Table 5).
Table 5 influence of turbid treating stranguria granule that disappear to the rat carrageenan foot swelling
| Dosage (gram/kilogram) | Mus number (only) | The scorching back swelling of system value (cm, X ± SD) (suppression ratio %) | |||
| 1h | 2h | 4h | |||
| Matched group | -- | 10 | 0.49±0.12 | 0.64±0.11 | 0.56±0.13 |
| Turbid treating stranguria granule disappears | 10.0 5.0 2.5 | 10 10 10 | 0.39±0.09* (20.4) 0.35±0.07** (28.6) 0.38±0.08* (22.4) | 0.45± 0.07** (29.7) 0.47± 0.05** (26.6) 0.50±0.13* (21.9) | 0.45±0.08* (19.6) 0.43±0.07* (23.2) 0.43±0.08* (23.2) |
| QIANLIETONG PIAN | 0.8 | 10 | 0.38±0.04* (22.4) | 0.53±0.12* (17.2) | 0.48±0.09 (14.3) |
Annotate: compare P＜0.05 with matched group, * * P＜0.01
3. to the bullate influence of rat granuloma
Method: rat makes abdominal incision under ether light anaesthesia aseptic condition, and it is subcutaneous that 20 milligrams sterilization cotton balls are implanted the both sides groin.The heavy random packet of postoperative junctor, operation began administration the same day, every day secondary, continuous 7 days, weighed earlier in the 8th day, behind the medicine 1 hour with the rat sacrificed by decapitation, peel off and take out the cotton balls granulation tissue, weigh after 12 hours in 60 ℃ of baking oven inner dryings, deduct cotton balls weight, be the granuloma dry weight, respectively organize granuloma weight, carry out statistical procedures.
Table 6 disappears turbid treating stranguria granule to the swollen outgrowth influence of rat granuloma (X ± SD)
| Group | Dosage (gram/kilogram) | Mus number (only) | Granuloma dry weight (milligram) | Suppression ratio (%) | The P value |
| Matched group | -- | 10 | 57.05±13.29 | ||
| Turbid treating stranguria granule disappears | 20.0 10.0 5.0 | 10 10 10 | 42.55±8.84 45.20±9.48 46.60±12.94 | 25.42 20.77 18.32 | ＜0.01 ＜0.01 ＜0.05 |
| QIANLIETONG PIAN | 0.8 | 10 | 46.15±10.96 | 19.11 | ＜0.01 |
By table 6 as seen, by significant inhibitory effect, the positive control drug QIANLIETONG PIAN is also by similar effect to granulation tissue hyperplasia for large, medium and small three the dosage groups of the turbid treating stranguria granule that disappears.
Three, the turbid treating stranguria particulate bacteriostatic experiment that disappears
1. external bacteriostatic experiment
By medicinal liquid doubling dilution in vitro: do two times of doubling dilutions with will disappear turbid treating stranguria granule (125 milligrams of milliliters), QIANLIETONG PIAN (62.5 mg/ml) of meat soup, each dilution factor is respectively established 2 pipes, every pipe adds 1 milliliter of the culture medium that contains different liquor strengths, add 105 bacterium/milliliter .0.1 milliliter bacterium liquid again, cultivation is 18 hours in 37 ℃ of incubators, observes in each pipe to have or not bacterial growth.
By table 7 as seen, cultivate after 18 hours, the antibacterial control tube all has bacterial growth.The turbid treating stranguria granule that disappears all has in various degree inhibitory action to the growths of 3 kinds of antibacterials (7 kinds of bacterial strains) such as beta hemolytic streptococcus, staphylococcus aureus, escherichia coli, from minimum inhibitory concentration, the most remarkable to the beta hemolytic streptococcus effect, staphylococcus aureus, escherichia coli take second place, and QIANLIETONG PIAN also has bacteriostasis in various degree.
The table 7 outer bacteriostasis (medicinal liquid dilution method in vitro) of turbid treating stranguria granule that disappears
| Strain name | Bacterium numbering | Minimum inhibitory concentration | The antibacterial contrast | Own control | ||
| Turbid treating stranguria granule disappears | QIANLIETONG PIAN | Ring third kills star | ||||
| Staphylococcus aureus | 2-18 2-19 2-20 | 125 + 125 | + + 62.5 | 0.2 0.2 0.2 | + | -- |
| Bacillus proteus | 1 2 12 | + + + | + + + | 0.2 0.2 0.2 | + | -- |
| Beta hemolytic streptococcus | 10 11 12 | 63 63 63 | 62.5 31.25 62.5 | 0.2 0.2 0.2 | + | -- |
| Escherichia coli | 23 24 25 | 125 125 + | + + + | 0.2 0.2 0.2 | + | -- |
Annotate: bacterial isolates is clinical separation strain, the no bacterial growth of "--" expression, and "+" expression has bacterial growth.
2. bacteriostatic test in the body
Beta hemolytic streptococcus is caused the influence of dead mouse
Method is pressed the body weight random packet with mice, administration, and the bacterial infection matched group gives and the isometric distilled water of medicinal liquid.Every day, gastric infusion was 2 times, continuous five days.The 4th day, get and increase 18 hours beta hemolytic streptococcus of bacterium (11 strain) bacterium liquid (200,000,000/milliliter), every 0.5 milliliter of mouse peritoneal injection (100,000,000/milliliter), make lethal hit, attack back 72 hour record animal dead numbers, calculate mortality rate, compare between organizing with X2.
Table 8 as seen, behind the mouse infection antibacterial 72 hours, 70% death of bacterial infection animals of control group; and the heavy dose of group of the turbid treating stranguria granule mouse death rate that disappears is 22%; compare with the bacterial infection matched group, significant difference is arranged, expression has significant protective effect to the mouse infection beta hemolytic streptococcus.
The table 8 turbid treating stranguria granule that disappears causes the influence of dead mouse to beta hemolytic streptococcus
| Group | Dosage (gram/kilogram) | Mus number (only) | Death toll | The P value | |
| (only) | (mortality rate %) | ||||
| The antibacterial matched group | -- | 20 | 14 | 70.00 | |
| Turbid treating stranguria granule disappears | 20.0 10.0 5.0 | 18 18 18 | 4 5 9 | 22.22 33.33 52.94 | ＜0.01 ＜0.1 |
| QIANLIETONG PIAN | 1.6 | 18 | 8 | 44.44 | |
Annotate: compare * P＜0.05 * * P＜0.01 with matched group
Four, analgesic activity
Adopt mouse writhing method: get 18-20 gram mice, by body weight random packet, gastric infusion, 1 hour mouse peritoneal is injected 0.2 milliliter of 0.8% acetic acid/only, observe in 20 minutes after 5 minutes and typically turn round the body frequency behind the medicine
Table 9 analgesic activity of turbid treating stranguria granule that disappear to mice
| Group | Dosage (gram/kilogram) | Mus number (only) | Turn round body number of times (X ± SD) | Suppression ratio (%) | The P value |
| Matched group | -- | 10 | 18.2±3.01 | ||
| Turbid treating stranguria granule disappears | 20.0 10.0 5.0 | 10 10 10 | 6.9±4.23## 8.4±3.37# 9.6±2.91 | 62.09 53.85 47.25 | ＜0.01 ＜0.01 ＜0.01 |
| QIANLIETONG PIAN | 1.6 | 10 | 11.9±2.51 | 34.62 | ＜0.01 |
Annotate: compare #P＜0.05 with QIANLIETONG PIAN, ##P＜0.01
By table 9 result as seen, three the dosage groups of turbid treating stranguria granule that disappear all can obviously reduce mice and cause the occurrence frequency of turning round body because of acetic acid stimulates, and its effect obviously is better than the positive control drug QIANLIETONG PIAN.
Five, the effect of invigorating blood circulation
Influence to the rabbit bulbar Conjunctiva Microcirculation
Method: rabbit is by the body weight random packet, administration, continuous 10 days, the test administration on the same day after 1 hour, with the 5 ml/kg intravenous anesthesias of 20% urethane, be placed on the microscope carrier, it is fixing to lie on one's side, cast oblique rays on bulbar conjunctiva with spotlight, observe left eye ball microcirculation, select blood flow more stable small artery and vein in same position to make field of view, inject 10% high molecular dextran (molecular weight little 580 fast from rabbit ear edge vein then, 00) normal saline solution 6 ml/kg cause acute microcirculation disturbance (slow blood flow, hemocyte is assembled).After the modeling 1 hour, observe the bulbar Conjunctiva Microcirculation situation of change.
Observation index: blood flow rate, hemocyte are assembled and are recovered normal person rabbit number substantially.
Flow velocity criterion (employing scoring method)
Linear flow: flow velocity is fast, is smooth streak, has no granular sensation, is designated as " 0 "; The grain linear flow: blood flow is slower, though become line continuously, obvious granular sensation is arranged, and is designated as " 1 "; Grain stream: blood flow is slow,, is designated as " 2 " as the silt sample; The grain unhurried current: blood flow is the silt sample, slowly flows continuously, is designated as " 3 "; Grain pendulum stream: blood flow is the silt sample, and obviously the silt agglomerate into stops, and swing is designated as " 4 "; Stagnate: blood flow stops fully, is designated as " 5 ".
Hemocyte is assembled:
Do not have poly-" 0 ", light poly-" 1 ", in poly-" 2 ", meet again " 3 ", compartment shape " 4 " is stagnated " 5 ".
Table 10 disappears turbid treating stranguria granule to the influence of rabbit bulbar Conjunctiva Microcirculation (X ± SD)
| Group | Dosage (gram/kilogram) | Number of animals (only) | Back 1 hour of little barrier | |
| Blood flow rate | Hemocyte is assembled | |||
| Matched group | -- | 10 | 6.45±1.36 | 6.51±1.74 |
| Turbid treating stranguria granule disappears | 12.0 | 6 | 1.58±0.49**## | 1.75±0.99**## |
| 6.0 | 6 | 1.67±0.52**## | 2.17±1.17**## | |
| 3.0 | 6 | 1.92±0.92**## | 2.50±1.61**# | |
| QIANLIETONG PIAN | 0.6 | 6 | 4.00±1.67** | 4.50±0.84** |
Compare * P＜0.05 with matched group, * * P＜0.01
Compare #P＜0.05 with QIANLIETONG PIAN, ##P＜0.01
The result: behind the intravenous injection high molecular dextran, blood flow obviously slows down, and arteriole, venule, blood capillary bore increase, and are the stasis state, and slow blood flow, the overwhelming majority are the grain unhurried current, and severe is assembled, and grain pendulum stream, compartment shape appear in animal out of the ordinary.Back 1 hour of little barrier, the matched group fluidised form is constant substantially, and all administration groups can see that all phenomenons such as fluidised form, flow velocity, gathering all have improvement in various degree, and blood flow rate is obviously accelerated, and erythrocyte aggregation obviously alleviates (table 10), and it is normal that major part has all been recovered.The positive control drug QIANLIETONG PIAN also improves significantly to the rabbit microcirculation disturbance, but effect is obviously not as disappearing turbid treating stranguria groups of grains.The prompting turbid treating stranguria granule that disappears has significant protective effect to rabbit microcirculation disturbance due to 10% high molecular dextran.
Six, the turbid treating stranguria particulate diuresis that disappears to rat
Method: select 180-200 gram male rat, by the body weight random packet, fasting is 18 hours before the test, can't help water, and each Mus is irritated stomach by 2 milliliters/100 grams and gives distilled water (medicine of administration group adds in the entry load), gently presses the rat hypogastric region to make the bladder emptying.Immediately rat is put into metabolic cage, 1 in every cage was collected urine, and was carried out statistical procedures with the urine value in 2,4 hours.
Table 11 diuresis of turbid treating stranguria granule that disappear to rat
| Group | Dosage (gram/kilogram) | Mus number (only) | Different time urine amount after the administration (hour) | |
| 2 | 4 | |||
| Matched group | -- | 10 | 1.65±0.80 | 3.87±1.09 |
| Turbid treating stranguria granule disappears | 10.0 | 10 | 2.75±0.86** | 5.21±0.79** |
| 5.0 | 10 | 2.67±0.96* | 5.15±0.94* | |
| 2.5 | 10 | 2.46±0.78* | 4.45±0.84 | |
| QIANLIETONG PIAN | 0.8 | 10 | 2.43±0.62* | 5.06±0.85* |
Compare * P＜0.05 with matched group, * * P＜0.01
Table 11 result as seen, the turbid treating stranguria granule that disappears has tangible diuresis to water load rat, heavy dose of group diuresis, heavy dose of group diuresis is the strongest, QIANLIETONG PIAN also has similar diuresis.
By above evidence, the turbid treating stranguria granule that disappears has:
1, rat aseptic prostatitis is had the obvious suppression effect, make that the little body density of Lecithin obviously raises in the prostatic fluid, total white blood cells obviously reduces; Rat chronic prostatitis adenomatosis is clearly better, and a matter inflammatory cell infiltration obviously alleviates, and the obvious treatment effect is arranged.
2, mice and rat acute, chronic inflammatory disease all there is the obvious suppression effect.The mouse ear edema that Oleum Tiglii is caused obviously alleviates, and reduces increasing of capillary of skin permeability, the ankle swelling in rat that the inhibition carrageenin causes and the formation of granuloma induced by implantation of cotton pellets.
3, the growth of external 3 swollen antibacterials (7 kinds of bacterial strains) all has inhibitory action in various degree; Death due to the mouse infection beta hemolytic streptococcus there is the certain protection effect.
4, this medicine of mouse writhing evidence has significant analgesia role.
5, rabbit microcirculation disturbance due to 10% high molecular dextran there is significant protective effect.
6, the load rat there is certain diuresis.
The turbid treating stranguria granule that disappears is obtained obvious curative effects to the treatment chronic prostatitis, and this medicine of our evidence all has the obvious treatment effect to acute (aseptic), chronic prostatitis; And in heat clearing away, invigorate blood circulation, there is obvious pharmacological action aspects such as analgesia, diuresis, for the clinical treatment chronic prostatitis provides certain pharmacodynamics basis.
Claims (8)
1, a kind of pharmaceutical composition for the treatment of prostatosis is characterized in that having the active component that is made by following raw materials according in per 1000 patent medicine:
Herba Lysimachiae 300-500 restrains cotton Bi 300-500 gram
Herba Dianthi 150-300 gram Cortex Phellodendri 200-300 gram
Radix Notoginseng 30-55 gram Semen Persicae 150-300 gram
Fructus Toosendan 200-300 gram Radix Linderae 150-250 gram
Radix Achyranthis Bidentatae 200-300 gram.
2, the pharmaceutical composition of treatment prostatosis according to claim 1 is characterized in that having the active component that is made by following raw materials according in per 1000 patent medicine:
Herba Lysimachiae 400-450 restrains cotton Bi 350-450 gram
Herba Dianthi 180-250 gram Cortex Phellodendri 230-280 gram
Radix Notoginseng 35-45 gram Semen Persicae 180-250 gram
Fructus Toosendan 230-280 gram Radix Linderae 180-250 gram
Radix Achyranthis Bidentatae 230-280 gram.
3, the pharmaceutical composition of treatment prostatosis according to claim 1 and 2 is characterized in that having the active component that is made by following raw materials according in per 1000 patent medicine:
Herba Lysimachiae 400-420 restrains cotton Bi 400-420 gram
Herba Dianthi 200-230 gram Cortex Phellodendri 230-260 gram
Radix Notoginseng 40-45 gram Semen Persicae 200-220 gram
Fructus Toosendan 230-250 gram Radix Linderae 200-220 gram
Radix Achyranthis Bidentatae 230-260 gram.
4,, it is characterized in that after adding conventional pharmacy adjuvant, making granule, tablet, capsule, powder or pill according to the pharmaceutical composition of the described treatment prostatosis of one of claim 1-3.
5, a kind of preparation of drug combination method for the treatment of prostatosis is characterized in that being made up of the following step:
A, take by weighing in following ratio:
Herba Lysimachiae 300-500 restrains cotton Bi 300-500 gram
Herba Dianthi 150-300 gram Cortex Phellodendri 200-300 gram
Radix Notoginseng 30-55 gram Semen Persicae 150-300 gram
Fructus Toosendan 200-300 gram Radix Linderae 150-250 gram
Radix Achyranthis Bidentatae 200-300 gram
B, get Herba Lysimachiae, cotton Bi and Cortex Phellodendri 70% alcohol reflux 3-5 time, each 1-2 hour, alcohol adding amount be the medical material amount 4-7 doubly, filter, merge alcohol extract, placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 2-4 time, each 0.5-1.5 hour, amount of water be the medical material amount 6-10 doubly, filter, being concentrated into relative density is 1.15-1.20, cools, and adds ethanol and makes and contain the alcohol amount and reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate, drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, Radix Notoginseng powder that adding (D) step obtains and dextrin or starch are an amount of, stevioside's 15 grams, mixing is used alcohol granulation, drying is made 1000 of granules altogether.
6, a kind of preparation of drug combination method for the treatment of prostatosis is characterized in that being made up of the following step:
A, take by weighing in following ratio:
Herba Lysimachiae 300-500 restrains cotton Bi 300-500 gram
Herba Dianthi 150-300 gram Cortex Phellodendri 200-300 gram
Radix Notoginseng 30-55 gram Semen Persicae 150-300 gram
Fructus Toosendan 200-300 gram Radix Linderae 150-250 gram
Radix Achyranthis Bidentatae 200-300 gram
B, get Herba Lysimachiae, cotton Bi and Cortex Phellodendri and add 70% alcohol reflux 4 times, each 1.5 hours, alcohol adding amount be the medical material amount 5-7 doubly, filter, merge alcohol extract, placement is spent the night, filter once more alcoholic solution;
C, get Herba Dianthi, Semen Persicae, Fructus Toosendan, the Radix Linderae and Radix Achyranthis Bidentatae, decoct with water 3 times, each 1.0 hours, amount of water be the medical material amount 8-9 doubly, filter, being concentrated into relative density is 1.15-1.20, cools, and adds ethanol and makes and contain the alcohol amount and reach 70%, cold preservation is spent the night, and sucking filtration gets filtrate;
D, get Radix Notoginseng chopping oven dry and pulverized 100 mesh sieves, Radix Notoginseng powder;
E, filtrate that (C) step is obtained merge with the alcoholic solution that (B) step obtains, and reclaim ethanol, concentrate drying under reduced pressure, get dry extract, pulverize, cross 100 mesh sieves, add the Radix Notoginseng powder that (D) step obtains, mixing, drying in incapsulating, obtains 1000 capsules altogether.
7,, it is characterized in that raw material consumption wherein is according to the preparation of drug combination method of claim 5 or 6 described treatment prostatosis:
Herba Lysimachiae 400-450 restrains cotton Bi 350-450 gram
Herba Dianthi 180-250 gram Cortex Phellodendri 230-280 gram
Radix Notoginseng 35-45 gram Semen Persicae 180-250 gram
Fructus Toosendan 230-280 gram Radix Linderae 180-250 gram
Radix Achyranthis Bidentatae 230-280 gram
Make 1000 altogether.
8,, it is characterized in that raw material consumption wherein is according to the preparation of drug combination method of claim 5 or 6 described treatment prostatosis:
Herba Lysimachiae 400-420 restrains cotton Bi 400-420 gram
Herba Dianthi 200-230 gram Cortex Phellodendri 230-260 gram
Radix Notoginseng 40-45 gram Semen Persicae 200-220 gram
Fructus Toosendan 230-250 gram Radix Linderae 200-220 gram
Radix Achyranthis Bidentatae 230-260 gram
Make 1000 altogether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100774501A CN1323688C (en) | 2005-06-23 | 2005-06-23 | Medicine composition for treating prostatosis and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100774501A CN1323688C (en) | 2005-06-23 | 2005-06-23 | Medicine composition for treating prostatosis and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698837A CN1698837A (en) | 2005-11-23 |
| CN1323688C true CN1323688C (en) | 2007-07-04 |
Family
ID=35475191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100774501A Active CN1323688C (en) | 2005-06-23 | 2005-06-23 | Medicine composition for treating prostatosis and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1323688C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537096B (en) * | 2008-03-19 | 2012-04-25 | 北京亚东生物制药有限公司 | Method for controlling quality of Chinese medicinal preparation for treating chronic prostatitis |
| US9682115B2 (en) * | 2012-04-02 | 2017-06-20 | Seipel Group Pty Ltd | Herbal compositions for the prevention or treatment of benign prostatic hyperplasia and related disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116937A (en) * | 1994-08-18 | 1996-02-21 | 王耀强 | Chinese herb medicine preparation for treating prostate hyperplasia and its preparing method |
| CN1187997A (en) * | 1997-01-13 | 1998-07-22 | 李国华 | Drug for curing stone of urinary system |
-
2005
- 2005-06-23 CN CNB2005100774501A patent/CN1323688C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116937A (en) * | 1994-08-18 | 1996-02-21 | 王耀强 | Chinese herb medicine preparation for treating prostate hyperplasia and its preparing method |
| CN1187997A (en) * | 1997-01-13 | 1998-07-22 | 李国华 | Drug for curing stone of urinary system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1698837A (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100337662C (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN1762967A (en) | Enoxolone derivative, preparation method and uses | |
| CN1839819A (en) | Medicinal composition containing tanshinone and its preparation process and usage | |
| CN1600318A (en) | Combination of Chinese traditional medicine for curing cardiovascular diseases and cerebrovascular disease | |
| CN1698713A (en) | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof | |
| CN1742876A (en) | Chinese medicine for treating tractures and preparation for making plaster thereof | |
| CN1917895A (en) | Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases | |
| CN1323688C (en) | Medicine composition for treating prostatosis and method for preparing the same | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1203872C (en) | Medicine for curing chronic colitis | |
| CN1513447A (en) | Application of bamboo leaf total flavone in medicine for treating and preventing prostata disease and health-care-food | |
| CN1323689C (en) | Medicine for treating prostatic accrementition and its preparation | |
| CN1836685A (en) | Use of catechu in preparing drug for treating hyperuricemia | |
| CN1197612C (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1290529C (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1868502A (en) | Medicine composition used for treating rheumatoid arthritis, and its prepn. method | |
| CN1207030C (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1742808A (en) | Medicine composition with synergetic function | |
| CN1076966C (en) | Medicine for curing diabetes and nephrosis and delaying chronic renal failure | |
| CN1772122A (en) | Indian stringbush prepn with antiphlogistic and detoxicating functions | |
| CN101077873A (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN101062314A (en) | Medicine for curing gout and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Asia-East Bio-Pharmaceutical Co., Ltd. Assignor: Xu Hongmo|Xu Ziqing Contract fulfillment period: 2009.7.8 to 2014.7.7 Contract record no.: 2009990000931 Denomination of invention: Medicine for treating prostate disease and method for preparing same Granted publication date: 20070704 License type: Exclusive license Record date: 20090817 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.7.8 TO 2014.7.7; CHANGE OF CONTRACT Name of requester: BEIJING YADONG BIOLOGY PHARMACY CO., LTD. Effective date: 20090817 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Beijing Asia-East Bio-Pharmaceutical Co., Ltd. Assignor: Xu Hongmo|Xu Ziqing Contract record no.: 2009990000931 Date of cancellation: 20140928 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210608 Address after: 102609 No.46 Simiao Road, Daxing biomedical industrial base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: Beijing rich church Pharmaceutical Technology Co.,Ltd. Address before: 100858 Beijing City, Haidian District Wanshou Road No. 28 South Gate No. 2 building 55 C Patentee before: Xu Hongmo Patentee before: Xu Ziqing |